{"entity":{"id":"nct07595874","kind":"trial","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","aka":["NEST3"],"tldr":"A phase 2 trial of balstilimab and botensilimab in colorectal cancer, run by City of Hope Medical Center, now recruiting.","summary":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 is a phase 2, interventional study registered as NCT07595874 by City of Hope Medical Center, with a registry enrolment figure of 100 participants, started 2026-12-27 and due to reach its primary completion in 2027-05-27. Interventions recorded: Balstilimab; Biospecimen Collection; Botensilimab; Computed Tomography; Magnetic Resonance Imaging. Conditions listed: Advanced Colon Adenocarcinoma; Advanced Colorectal Adenocarcinoma; Advanced Rectal Adenocarcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIB Rectal Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage IIC Rectal Cancer AJCC v8; Stage IIIA Colon Cancer AJCC v8; Stage IIIA Rectal Cancer AJCC v8; Stage IIIB Colon Cancer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Colon Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8. Primary outcome: Two-year disease-free survival rate. Colorectal eligibility wording from the registry: \"* Histologically confirmed or cytologically confirmed colorectal adenocarcinoma\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07595874","url":"https://clinicaltrials.gov/study/NCT07595874"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["balstilimab","botensilimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07595874","phase":"2","setting":"A Phase II Novel Exploratory Study to Test Neoadjuvant Immunotherapy Combinations in Patients With Resectable Colon Cancer (NEST3)","sponsor":"City of Hope Medical Center","enrolled":100,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07595874/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"balstilimab","kind":"drug","name":"Balstilimab","route":"/drugs/balstilimab/"},{"id":"botensilimab","kind":"drug","name":"Botensilimab","route":"/drugs/botensilimab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}